William S. Kingston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William S. Kingston has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Andrea M. Kuczynski
University of Calgary, Calgary, AB, Canada
1 shared publication James Jh. Im
Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada
1 shared publication- Monica E. Maher
Division of Neurology, University of Toronto, Toronto, Canada
1 shared publication
Latest Publications
- 9 December 2025
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 25 (1) , 82
Headache After Stroke: An Update for the Clinician
Headache in the context of stroke is common and represents significant morbidity in the acute and outpatient settings. This article reviews recent research on the incidence, pathophysiology and management of headache secondary to ischemic and hemorrhagic stroke. Multiple studies have attempted to characterize the incidence and risk factors of post-stroke headache. Some studies regarding proposed pathophysiology exist but no clear consensus has been reached. Management strategies are limited and are typically guided by harm reduction rather than efficacy. There are some studies indicating that procedural based therapies can be both safe and effective with multiple ongoing trials focusing on ganglion blocks. The use of calcitonin-gene related peptide based therapies are limited in this setting with no robust evidence to its safety or efficacy. Headache following ischemic stroke and hemorrhagic stroke is prevalent and likely impedes recovery and quality of life. Management options are limited, though studies show promising initial results and trials are ongoing.
- 9 December 2025
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 25 (1) , 82
Headache After Stroke: An Update for the Clinician
Headache in the context of stroke is common and represents significant morbidity in the acute and outpatient settings. This article reviews recent research on the incidence, pathophysiology and management of headache secondary to ischemic and hemorrhagic stroke. Multiple studies have attempted to characterize the incidence and risk factors of post-stroke headache. Some studies regarding proposed pathophysiology exist but no clear consensus has been reached. Management strategies are limited and are typically guided by harm reduction rather than efficacy. There are some studies indicating that procedural based therapies can be both safe and effective with multiple ongoing trials focusing on ganglion blocks. The use of calcitonin-gene related peptide based therapies are limited in this setting with no robust evidence to its safety or efficacy. Headache following ischemic stroke and hemorrhagic stroke is prevalent and likely impedes recovery and quality of life. Management options are limited, though studies show promising initial results and trials are ongoing.
- Open Access
- 8 May 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 65 (6) , 1041-1043
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
Calcitonin gene‐related peptide (CGRP) is a potent cerebral vasodilator and part of the trigeminal migraine cascade. Newer migraine therapies target CGRP signaling for both acute and preventative management of headache. In this series, we present two cases of genetic conditions, of which migraine is a key feature, responsive to CGRP antagonist therapy. A 31‐year‐old female with mitochondrial encephalopathy with lactic acidosis and stroke‐like episodes and a phenotype of chronic migraine with visual aura, and a 62‐year‐old female with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy with a phenotype of chronic migraine and side‐locked headache with cranial autonomic symptoms. Each experienced a significant reduction in the frequency of their migraine attacks with monoclonal antibody treatment against CGRP. In this case series, we add to the growing body of evidence that CGRP‐blocking medications are safe and effective in some heritable neurological disorders in which vasomodulation is a common underlying pathology. To our knowledge, we present the first cases of galcanezumab use in an individual with mitochondrial encephalopathy with lactic acidosis and stroke‐like episodes and eptinezumab in an individual with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
- 8 May 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 65 (6) , 1041-1043
Open AccessGenetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
Calcitonin gene‐related peptide (CGRP) is a potent cerebral vasodilator and part of the trigeminal migraine cascade. Newer migraine therapies target CGRP signaling for both acute and preventative management of headache. In this series, we present two cases of genetic conditions, of which migraine is a key feature, responsive to CGRP antagonist therapy. A 31‐year‐old female with mitochondrial encephalopathy with lactic acidosis and stroke‐like episodes and a phenotype of chronic migraine with visual aura, and a 62‐year‐old female with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy with a phenotype of chronic migraine and side‐locked headache with cranial autonomic symptoms. Each experienced a significant reduction in the frequency of their migraine attacks with monoclonal antibody treatment against CGRP. In this case series, we add to the growing body of evidence that CGRP‐blocking medications are safe and effective in some heritable neurological disorders in which vasomodulation is a common underlying pathology. To our knowledge, we present the first cases of galcanezumab use in an individual with mitochondrial encephalopathy with lactic acidosis and stroke‐like episodes and eptinezumab in an individual with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
- 11 May 2021
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 21 (7) , 1-4
Retinal Migraine: Evaluation and Management
Purpose of Review This review aims to summarize the last 15 years of literature and case reports detailing retinal migraine—an uncommon and somewhat poorly understood migraine variant. Recent Findings In the last 15 years, only 12 cases of retinal migraine have been outlined. Similar to other migraine statistics, retinal migraine appears to affect women more so than men and presents with unilateral headache which tends to be ipsilateral to the side of vision loss. The pathophysiology may relate to vasoconstriction of retinal vessels, as evidenced by ictal fundus photography in the past few years. Summary Retinal migraine is a rare entity, with a paucity of described cases in the literature. Retinal migraine is a diagnosis of exclusion, as monocular vision loss might be ascribed to several concerning disorders requiring urgent diagnosis and treatment, and any patient presenting as such should be thoroughly investigated. Patients suffering from retinal migraine appear to respond to typical migraine abortive therapies including NSAIDs and migraine prophylactic medications.
- 11 May 2021
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 21 (7) , 1-4
Retinal Migraine: Evaluation and Management
Purpose of Review This review aims to summarize the last 15 years of literature and case reports detailing retinal migraine—an uncommon and somewhat poorly understood migraine variant. Recent Findings In the last 15 years, only 12 cases of retinal migraine have been outlined. Similar to other migraine statistics, retinal migraine appears to affect women more so than men and presents with unilateral headache which tends to be ipsilateral to the side of vision loss. The pathophysiology may relate to vasoconstriction of retinal vessels, as evidenced by ictal fundus photography in the past few years. Summary Retinal migraine is a rare entity, with a paucity of described cases in the literature. Retinal migraine is a diagnosis of exclusion, as monocular vision loss might be ascribed to several concerning disorders requiring urgent diagnosis and treatment, and any patient presenting as such should be thoroughly investigated. Patients suffering from retinal migraine appear to respond to typical migraine abortive therapies including NSAIDs and migraine prophylactic medications.